RE: Reduced exposure31 Jul 2020 00:35
@safy - I have made requests to know that answer directly to the company and like everyone on here you get the investors relations team answering which is basically just rehashing the RNS. So they were ok to confirm the India submission but any questions related to FDA was responded with complete silence. So it makes me nervous and I reduced my position accordingly. If the RNS comes out and I miss out so be it, it does not bother me, there are other opportunities. If I can find evidence which gives me confidence in the FDA timeline expectations then I'll probably buy back into my full position. However what also concerns me is even when the approvals come through this expectation that sales will swiftly follow I am unconvinced off. The testing market is full of companies now so it isn't like when NCYT had first shot, people were desperate back in March for test kits and NCYT did a cracking job.
As for this bb, its boring listening to the same rampers everyday on here, lacking facts or objective critical analysis, just keep telling you tomorrow is all going to happen. Broken clock and all eventually they will get it right once, more on pure luck than any skill is reasoning. When I see bb with these consistent rampers it is a yellow flag.
I would be delighted if tomorrow the RNS comes out and all is good for GDR shareholders, I believe they have a decent product but the management lack of communication with the Market and leaving so many unanswered questions which surely are not price sensitive is concerning. ODX seemed to learn from their communication issues, it seems that GDR are not interested in the pi's.